These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36597886)

  • 41. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history.
    Kiszel P; Sík P; Miklós J; Kajdácsi E; Sinkovits G; Cervenak L; Prohászka Z
    Sci Rep; 2023 Aug; 13(1):13166. PubMed ID: 37574522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 vaccines and myocarditis.
    Sularz AK; Hua A; Ismail T
    Clin Med (Lond); 2023 Sep; 23(5):495-502. PubMed ID: 37775180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
    Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
    Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines.
    Hickey TE; Kemp TJ; Bullock J; Bouk A; Metz J; Neish A; Cherry J; Lowy DR; Pinto LA
    Hum Vaccin Immunother; 2023 Aug; 19(2):2215677. PubMed ID: 37264688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
    Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
    J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.
    Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD
    Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.
    Piechotta V; Siemens W; Thielemann I; Toews M; Koch J; Vygen-Bonnet S; Kothari K; Grummich K; Braun C; Kapp P; Labonté V; Wichmann O; Meerpohl JJ; Harder T
    Lancet Child Adolesc Health; 2023 Jun; 7(6):379-391. PubMed ID: 37084750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
    Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J
    Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
    Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
    Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of SARS-CoV-2 vaccination in adolescents with cardiac disease.
    Hayashi H; Narita J; Ishii R; Hirose M; Hashimoto K; Yamagishi Y; Ozono K; Nakagami H; Ishida H
    Pediatr Int; 2022 Jan; 64(1):e15329. PubMed ID: 36310037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.
    Ogata AF; Cheng CA; Desjardins M; Senussi Y; Sherman AC; Powell M; Novack L; Von S; Li X; Baden LR; Walt DR
    Clin Infect Dis; 2022 Mar; 74(4):715-718. PubMed ID: 34015087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chappell KJ; Mordant FL; Amarilla AA; Modhiran N; Liang B; Li Z; Wijesundara DK; Lackenby JA; Griffin P; Bennet JK; Hensen L; Zhang W; Nguyen THO; Tran MH; Tapley P; Barnes J; Reading PC; Kedzierska K; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
    EBioMedicine; 2023 Nov; 97():104842. PubMed ID: 37865043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
    Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
    Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.